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Abstract
Background: We have previously identified 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the bioactive form of vitamin D3,
as a potent regulator of energy-utilization and nutrient-sensing pathways in prostate cancer cells. In the current study,
we investigated the effects of 1,25(OH)2D3 on breast cancer (BCa) cell metabolism using cell lines representing distinct
molecular subtypes, luminal (MCF-7 and T-47D), and triple-negative BCa (MDA-MB-231, MDA-MB-468, and HCC-1143).
Methods: 1,25(OH)2D3’s effect on BCa cell metabolism was evaluated by employing a combination of real-time
measurements of glycolysis/oxygen consumption rates using a biosensor chip system, GC/MS-based metabolomics,
gene expression analysis, and assessment of overall energy levels. The influence of treatment on energy-related
signaling molecules was investigated by immunoblotting.
Results: We show that 1,25(OH)2D3 significantly induces the expression and activity of the pentose phosphate
pathway enzyme glucose-6-phosphate dehydrogenase (G6PD) in all BCa cell lines, however differentially influences
glycolytic and respiratory rates in the same cells. Although 1,25(OH)2D3 treatment was found to induce seemingly anti-
oxidant responses in MCF-7 cells, such as increased intracellular serine levels, and reduce the expression of its putative
target gene thioredoxin-interacting protein (TXNIP), intracellular reactive oxygen species levels were found to be
elevated. Serine accumulation in 1,25(OH)2D3-treated cells was not found to hamper the efficacy of chemotherapeutics,
including 5-fluorouracil. Detailed analyses of the nature of TXNIP’s regulation by 1,25(OH)2D3 included genetic and
pharmacological inhibition of signaling molecules and metabolic enzymes including AMP-activated protein kinase and
G6PD, as well as by studying the ITCH (E3 ubiquitin ligase)-TXNIP interaction. While these investigations demonstrated
minimal involvement of such pathways in the observed non-canonical regulation of TXNIP, inhibition of estrogen
receptor (ER) signaling by tamoxifen mirrored the reduction of TXNIP levels by 1,25(OH)2D3, demonstrating that the
latter’s negative regulation of ER expression is a potential mechanism of TXNIP modulation.
Conclusions: Altogether, we propose that regulation of energy metabolism contributes to 1,25(OH)2D3’s anti-
cancer effects and that combining 1,25(OH)2D3 with drugs targeting metabolic networks in tumor cells may lead
to synergistic effects.
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Background
Breast cancer (BCa) is the main cause of cancer death in
females in both developed and developing countries [1].
Several risk factors have been implicated in the patho-
genesis of the disease, including lifestyle-related factors,
for example smoking, obesity, and physical inactivity, as
well as genetic factors, like mutations in breast cancer
susceptibility genes (BRCA 1 and 2) [1, 2]. In addition to
these risk factors, mounting evidence has demonstrated
that vitamin D deficiency contributes to both BCa inci-
dence and survival [3, 4].
Vitamin D is a seco-steroid that is produced in
humans upon exposure of the skin to ultraviolet-B radi-
ation [5]. The resulting hormonal precursor molecule is
further metabolized to yield its hormonally active
form—1,25-dihydroxyvitamin D (1,25(OH)2D3, also
known as calcitriol)—through a hydroxylation step in
the liver, followed by a second activating hydroxylation
in the kidneys [5]. 1,25(OH)2D3 subsequently binds to
its nuclear vitamin D receptor (VDR), present in diverse
cell types, and regulates the expression of hundreds of
genes known to influence proliferation, differentiation,
and angiogenesis [5]. Both in vitro and animal studies
have illustrated that 1,25(OH)2D3 and its analogues are
promising chemotherapeutics against BCa [3, 6], with re-
ports showing induction of cell cycle arrest and apop-
tosis, as well as regulation of estrogen signaling with
treatment [3, 6]. Additionally, studies have shown that
VDR expression inversely correlates with breast cancer
mortality and that CYP24A1, the vitamin D-catabolizing
enzyme, is a putative oncogene [6].
BCa is classified into a number of molecular subtypes,
namely (i) basal-like, also known as triple-negative BCa
(TNBC) due to the absence of estrogen receptor (ER), pro-
gesterone receptor, and HER2; (ii) luminal A/B, character-
ized by the presence of ER; and finally, (iii) HER2 positive
BCa, with amplified ERBB2 gene expression [7, 8]. Clinic-
ally, these subtypes exhibit different responsiveness to
chemotherapy and thus are administered different therapy
regimens [9]. For example, luminal BCa is typically treated
with chemotherapeutics that interfere with ER signaling,
such as anti-estrogens and aromatase inhibitors [10].
Additionally, although controversial, different BCa sub-
types exhibit distinct aberrations in their metabolic pro-
files [10, 11]. For instance, ER+ BCa has been shown to
exhibit more “classical” Warburg metabolism, illustrated
by an increase in glucose consumption and lactate pro-
duction, whereas ER− BCa is known to rely more on glu-
tamine metabolism and subsequent TCA replenishment/
anaplerosis [10]. Moreover, metabolic adaptation has been
reported as a potential resistance mechanism, which BCa
cells adopt in response to hormone therapy [12]. There-
fore, identification of drugs that target these altered meta-
bolic networks may prove beneficial in the treatment of
BCa as monotherapies, as well as enhance the efficacy/re-
duce resistance associated with currently established
chemotherapeutics.
Recent work has shown that 1,25(OH)2D3 modulates
glucose, glutamine, and fatty acid metabolism in several
experimental models including breast and prostate cancer
cells [13–17], which prompted us to thoroughly evaluate
the ability of this molecule to regulate metabolic networks
in BCa cell lines representing different molecular sub-
types. The effect of 1,25(OH)2D3 on energy metabolism of
luminal (MCF-7 and T-47D) and TNBC (MDA-MB-231,
MDA-MB-468, and HCC-1143) cells was evaluated using
real-time measurements of glycolytic/respiratory rates,
GC/MS-based quantification of TCA cycle intermediates
and diverse amino acids, mRNA expression analysis of
metabolism-related genes, and finally overall energy
charge. 1,25(OH)2D3 was found to induce both similar
and different metabolic effects in these cell lines, such as
induction in glucose-6-phosphate dehydrogenase (G6PD)
expression and activity in all cell lines, and disparate
regulation of glycolytic and respiratory capacities. In
MCF-7 cells, seemingly pro-survival metabolic pertur-
bations induced by treatment, such as accumulation of
intracellular serine, were not found to antagonize the
anti-tumor efficacy of chemotherapeutics including
5-fluorouracil (5-FU). Furthermore, 1,25(OH)2D3 was
found to negatively regulate TXNIP expression in
MCF-7 cells, possibly through reduction of estrogen re-
ceptor (ER) expression.
Methods
Cell culture
The human BCa cell lines MCF-7, T-47D, MDA-MB-231,
MDA-MB-468, and HCC-1143 were cultured in Dulbec-
co’s Modified Eagle Medium (DMEM) (Gibco, Germany)
containing 10% FCS (v/v) (Gibco, Germany) and 1% peni-
cillin/streptomycin (v/v) (Gibco, Germany) and kept in a
standard cell culture incubator (37 °C; 5% CO2). T-47D,
MDA-MB-468, and HCC-1143 were kind gifts from Dr.
Stefan Wiemann (DKFZ, Heidelberg). 1,25(OH)2D3
(Cayman Chemical-Biomol GmbH, Germany) treat-
ments were performed for the various indicated time
points in standard medium, at a final concentration of
100 nM. Additional drugs used in the study were added
to either fresh or conditioned medium for different time
points (as described in the “Results” section) and included
10 mM 2-deoxyglucose (Fluka-Sigma-Aldrich, Germany),
5 μM MG-132 (Sigma-Aldrich, Germany), 20 μM leupeptin
(Sigma-Aldrich, Germany), 100 nM calcipotriol (Cayman
Chemical-Biomol GmbH, Germany), and 20 μM
BAPTA-AM (Cayman Chemical-Biomol GmbH, Germany),
as well as increasing concentrations of dehydroepiandros-
terone (DHEA) (Cayman Chemical-Biomol GmbH,
Germany), Na Oxamate (Cayman Chemical-Biomol GmbH,
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Germany), AZD-3965 (Cayman Chemical-Biomol GmbH,
Germany), 5-fluorouracil (5-FU) (Fluka-Sigma-Aldrich,
Germany), and CBR-5884 (Cayman Chemical-Biomol
GmbH, Germany).
RNA isolation, cDNA synthesis, and RT-qPCR
BCa cells were treated with 1,25(OH)2D3 (100 nM) for
72 h, after which total RNA was isolated using QIAzol
lysis reagent (Qiagen, Germany), following the manufac-
turer’s instructions. RNA concentration and purity were
determined using NanoDrop 2000 UV-Vis Spectropho-
tometer (Thermo Scientific, Germany). cDNA was syn-
thesized from 500 ng of total RNA/sample using
ProtoScript® II first strand cDNA synthesis kit (New
England BioLabs, Germany). The thermal cycle qTower
(Analytik Jena AG) was used to assess mRNA expression
of various genes in real time. Primers used in the study
are listed in Additional file 1: Table S1. The LightCycler®
480 SYBR Green I Master (Roche, Germany) reaction mix
was used. The ΔΔCt method was used to calculate the
relative expression of the investigated genes in response to
treatment, with vinculin as the housekeeping gene.
RNA interference
Anti-AMPKα1 and anti-G6PD siRNAs were synthe-
sized by Riboxx (Riboxx GmbH, Radebeul, Germany)
(Additional file 2: Table S2). MCF-7 cells were
transfected with negative control, anti-AMPKα1, or
anti-G6PD oligonucleotides as described in an earlier
study [16]. Briefly, 50 pmol of the respective siRNA was
diluted in 100 μL Opti-MEM Reduced Serum Medium
(Gibco, Germany)/well in a 24-well plate and com-
plexed with the 1.5 μL transfection reagent Lipofecta-
mine® 3000 (Thermo Fischer, Germany)/well. Sixty
thousand cells suspended in 500 μL of DMEM (10%
FCS, without antibiotics) were added to each well and
mixed gently. The plate was kept overnight in a stand-
ard incubator, and the treatment was performed on the
following day as indicated.
On-line measurement of extracellular acidification,
oxygen consumption, and impedance using BIONAS 2500
Changes in cellular glycolytic, respiratory, and imped-
ance rates were monitored in response to 1,25(OH)2D3
(100 nM) treatment using the Bionas 2500 biosensor
chip system (Bionas, Rostock, Germany) as previously
described [16, 18]. Briefly, 6 sensor chips (SC1000) were
seeded with BCa cells at a density of 200,000 cells/chip
in 450 μL of full medium and kept in a standard cell cul-
ture incubator overnight. The 6 chips were then trans-
ferred to the sensor chip system, where either 3 were
continuously fed running medium (RM) containing ei-
ther DMSO or 1,25(OH)2D3. The RM used was prepared
from DMEM powder (Pan-Biotech GmbH, Germany)
containing neither glucose, sodium pyruvate, L-glutamine,
NaHCO3, nor phenol red. The medium was then supple-
mented with 1 g/L glucose, 2 mM glutamine, 1 mM
HEPES, and 10 mg/L phenol red. Additionally, 0.1% (v/v)
FCS and 1% (v/v) penicillin/streptomycin were added.
Data were analyzed using the software provided by the
manufacturer.
Glucose uptake and ATP measurements
With regard to glucose uptake, culture medium was
replaced with medium containing the 50 μM of the
fluorescently labeled glucose analogue, 2-[N-(7-nitro-
benz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose
(2-NBDG) (Cayman Chemical-Biomol GmbH, Germany),
at the end of the indicated treatment periods. Cells were
harvested 2 h later, and FACS analysis was performed to
determine the amount of intracellular 2-NBDG.
Intracellular ATP levels were assessed using the
ATPlite™ 1 step (Perkin Elmer, Germany), following the
manufacturer’s instructions. Cells were seeded at a dens-
ity of 5000 cells/well in a black 96-well plate with a
transparent bottom and placed inside a standard cell
culture incubator overnight. The cells were then treated
for 24 h with 100 μL of full medium containing either
DMSO or 1,25(OH)2D3 (100 nM), after which 100 μL of
the substrate solution was added to the wells, and lumi-
nescence was measured kinetically using the Tecan Ultra
plate reader (Tecan, Germany). The signal obtained
from each well was then normalized to the correspond-
ing protein content.
Analysis of glucose-6-phosphate dehydrogenase (G6PD)
enzymatic activity
G6PD enzymatic activity was determined as previously
described [19, 20]. The increase in absorbance resulting
from the NADP+ to NADPH reduction was measured at
345 nm. NADPH is generated in the first and third
reactions of the oxidative phase of the pentose
phosphate pathway (PPP), namely the conversion of G6P
to 6-phosphogluconolactone and 6-phosphogluconate
to ribose-5-phosphate, catalyzed by G6PD and
6-phosphogluconate dehydrogenase, respectively. The
combined activities of both enzymes were determined
by obtaining crude extracts containing 500 ng total pro-
teins from different cell lines treated for 72 h with either
1,25(OH)2D3 (100 nM) or DMSO and adding them to a
solution containing 2 mM glucose-6-phosphate, 1 mM
NADP+, and the reaction mixture (50 mM Tris/HCl buf-
fer, pH 8.2, 100 mM KCl, 5 mM MgSO4), reaching a final
volume of 100 μL. The activity of 6-phosphogluconate de-
hydrogenase was also measured by incubating 500 ng total
proteins with 2 mM 6-phosphogluconate, 1 mM NADP+,
and the aforementioned reaction mixture, reaching a final
volume of 100 μL. The increase in absorbance obtained
Abu el Maaty et al. Cancer & Metabolism  (2018) 6:11 Page 3 of 18
from both reactions was kinetically measured at 345 nm
using the Tecan Ultra plate reader (Tecan, Germany), and
the increase in absorbance associated with G6PD activity
was determined as the different between the two reactions.
Western blotting
After respective treatments were performed, cells were
washed once with PBS and lysed with urea buffer con-
taining a mixture of protease and phosphatase inhibitors
(leupeptin, pepstatin, PMSF, aprotinin, sodium orthova-
nadate, and sodium pyrophosphate). Protein content in
lysates was determined using Bradford assay (Sigma-Al-
drich, Germany). Fifty micrograms of total proteins was
resolved using SDS-PAGE and transferred onto a PVDF
membrane (GE Healthcare, Germany). Membranes were
blocked in blocking solution (5% milk in TBS/Tween)
for 1 h at RT. Incubation with primary antibodies (di-
luted according to the manufacturer’s instructions in 5%
BSA in TBS/Tween) was performed overnight at 4 °C.
Anti-phosphorylated ACC (S79), total ACC, phosphory-
lated AMPK (T172), total AMPK , ITCH, and ubi-
quitin (Ub) antibodies were obtained from Cell Signaling
Technology; anti-TXNIP (VDUP1) antibody was pur-
chased from MBL; anti-ß-actin, vinculin, and estrogen
receptor (ER) antibodies were purchased from Santa
Cruz Biotechnology; and anti-G6PD antibody were pur-
chased from Abgent. The membranes were incubated
with anti-rabbit or anti-mouse IgG horseradish
peroxidase-linked secondary antibodies (Cell Signaling
Technology) for 1 h at RT, after which membranes were
washed 3 times at RT using TBS/Tween. The horseradish
peroxidase substrate Western Lightning™ Plus ECl (Perkin
Elmer, Germany) was used, and target proteins were visu-
alized using the Fujifilm LAS-3000 imaging system.
Co-immunoprecipitation
MCF-7 cells were seeded in culture dishes until 80%
confluency and then treated for 24 h with either DMSO
or 1,25(OH)2D3. An additional control using MG-132
(6 h) was also used. Cells were then lysed as previously
described, and samples were pre-cleared by incubating
them with 0.25 mg of pre-washed protein A/G magnetic
beads (Thermo Fischer, Germany) for 20 min at room
temperature with rotation. The sample was then sepa-
rated from the beads and incubated overnight with 2 μg
of the antibody or an isotype specific control (Santa
Cruz Biotechnology, Germany) at 4 °C with rotation.
0.25 mg of pre-washed protein A/G magnetic beads was
then added to each sample, which was then incubated
for 1 h at room temperature with rotation. Magnetic
beads were then separated and then incubated with
100 μL of SDS-PAGE reducing buffer for 10 min at
room temperature with rotation. Western blotting was
then performed using the samples.
Intracellular ROS measurements
Intracellular ROS levels in DMSO- and 1,25(OH)2D3--
treated MCF-7 cells were assessed using dihydroethi-
dium (DHE) (Biomol GmbH, Germany) and MitoSox
Red (Thermo Fischer, Germany) staining. DHE is oxi-
dized by superoxide to produce the fluorescent product
oxyethidium, whereas the latter dye specifically detects
mitochondrial superoxide. For DHE staining, MCF-7
cells were seeded in a μ-slide 8-well chamber (Ibidi,
Germany) at a density of 30,000 cells/chamber and kept
overnight in a standard cell culture incubator. Cells were
then treated with DMSO or 1,25(OH)2D3 for 72 h, after
which the medium was replaced with phenol red-free
DMEM containing 2 μM Hoechst (Thermo Fischer,
Germany), and cells were placed inside an incubator for
10 min. Medium was then replaced with phenol red-free
DMEM containing 30 μM DHE and incubated for 15
mins, after which the medium was replaced with fresh
phenol red-free DMEM, and images were taken using a
fluorescence microscope (BZ9000, KEYENCE). Fluores-
cence intensity of DHE was quantified using ImageJ and
normalized to DMSO-treated cells.
For MitoSox Red staining, MCF-7 cells were seeded in
a 24-well plate at a density of 50,000 cells/well and
treated for 72 h with either DMSO or 1,25(OH)2D3.
Cells were then incubated with FCS-free DMEM con-
taining 2 nM MitoTracker Green (Thermo Fischer,
Germany) for 15 min. Medium was then replaced with
fresh DMEM containing 5 μM MitoSox Red, and then,
cells were incubated for 15 min. Medium containing the
dye was then replaced with phenol red-free medium,
and time-lapse images (every 15 min) were taken using
IncuCyte ZOOM live cell analysis system (Essen Bio-
Science, Germany). The Incucyte software 2016b was
used to analyze the signal intensity based on a fluores-
cent area mask, with a top hat filter applied for dead cell
exclusion due to enhanced auto-fluorescence. Four pic-
tures per well were used to calculate the overall signal
per well, and each condition was performed in 4 wells.
Gas chromatography/mass spectrometry (GC/MS) analysis
of metabolites/amino acids
Extraction
One hundred eighty microliters of 100% MeOH was added
to frozen pellets, containing approximately 3.0 × 106 cells,
and subjected to vigorous shaking for 15 min at 70 °C.
Ribitol was used as internal standard, and 5 μL of a
0.2 mg/ml stock was added to each sample. One hundred
microliters of chloroform were then added, and samples
were incubated for 5 min at 37 °C. Two hundred microli-
ters of water were added to samples, which were then cen-
trifuged at 11,000 g for 10 min to separate polar and
organic phases. For derivatization, the polar phase (300 μL)
was transferred to a new tube and dried using a speed-vac.
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Derivatization (silylation and methoximation)
Twenty microliters of methoximation reagent containing
20 mg/ml methoxyamine hydrochloride (Sigma-Aldrich,
Germany, 226,904) in pyridine (Sigma-Aldrich, Germany,
270,970) were used to dissolve the pellets. Samples were
then incubated for 2 h at 37 °C with shaking. 32.2 μL of
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA;
Sigma-Aldrich, Germany, M7891) and 2.8 μL of Alkane
Standard Mixture (50 mg/ml C10–C40; Fluka-Sigma-Aldrich,
Germany, 68,281) were also added to samples for silylation.
Samples were incubated at 37 °C for 30 min, after which
they were transferred to glass vials for GC/MS analysis.
GC/MS analysis
The GC/MS-QP2010 Plus (Shimadzu®) fitted with a
Zebron ZB 5MS column (Phenomenex®; 30 m ×
0.25 mm × 0.25 μm) was used. An injection temperature
of 230 °C was used, and 1 μL of each sample was
injected with split 10 mode. The temperature program
was initiated with a hold at 40 °C for 1 min, followed by
a ramp of 6 °C/min to 210 °C, another 20 °C/min ramp
till 330 °C, and a bake-out at 330 °C for 5 min, with he-
lium as a carrier gas with constant linear velocity. The
MS was employed with ion source and interface temper-
atures of 250 °C. A scan range (m/z) of 40–700 with a
0.2 s event time was used. For data processing, the
“GCMS solution” software (Shimadzu®) was utilized.
SRB assay
The sulforhodamine B (SRB) assay was performed as
previously described [21, 22]. Cells were seeded at a
density of 5000 cells/well in 96-well culture plates and
were treated with the different molecules using the indi-
cated concentrations and treatment periods. Serine and
glycine deprivation studies were performed using serine-
and glycine-free DMEM supplemented with dialyzed
FCS (10% v/v) and penicillin/streptomycin (1% v/v).
Serine or glycine was added to the medium at a final
concentration of 0.4 mM. Serine- and/or glycine-free
medium was treated with either DMSO or 1,25(OH)2D3,
and SRB assay was performed 72 h later. At the end of
the treatment period, cells were fixed by adding 100 μL
10% trichloroacetic acid per well. Culture plates were in-
cubated at 4 °C for 1 h, after which the plates were
washed three times with water. After drying the plates,
100 μL 0.054% SRB solution (SRB powder (Santa Cruz
Biotechnology) in 1% acetic acid) were added to each
well and incubated for 1 h at RT. SRB solution was sub-
sequently discarded, and wells were washed with
200 μL/well 1% acetic acid. After drying the plates, the
SRB dye was solubilized using 10 mM Tris (pH 10.5),
and the absorbance was measured at 535 nm using the
Tecan Ultra plate reader (Tecan, Germany).
Statistical analyses
Data were analyzed using Microsoft Excel and Graphpad
Prism. Densitometric analysis was performed using the
ImageJ software. Statistical significance of observed
changes in a measured parameter between DMSO- and
1,25(OH)2D3-treated cells was determined using a Stu-
dent’s t test. A p value less than or equal to 0.05, 0.01,
and 0.001 is denoted on figures by *, **, and ***, respect-
ively. Error bars represent SD. Available datasets of Affy-
metrix microarray profiling of breast tumors were used
(www.kmplot.com) [23]. The median of G6PD expres-
sion (probe ID 202275_at) separated tumors into those
with high- and low-G6PD expression. Logrank p values
and the hazard ratio (HR) (95% confidence interval) are
calculated.
Results
1,25(OH)2D3 induces similar and disparate effects on
glucose metabolism in different BCa cell lines
As previously mentioned, several recent studies have dem-
onstrated that 1,25(OH)2D3 induces metabolic changes in
different cancer models including BCa. To confirm this in
the BCa cell lines included in this study, we employed a
biosensor chip system that measures in real time, changes
in extracellular acidification, oxygen consumption, and
impedance. We observed clear differences in the meta-
bolic response of all cell lines to 1,25(OH)2D3 treatment.
In luminal breast cancer cells (MCF-7 and T-47D cells),
1,25(OH)2D3 markedly induced the acidification rate grad-
ually over the investigated time course, but did not signifi-
cantly impact the respiratory rate (Fig. 1a). On the other
hand, 1,25(OH)2D3 was found to reduce respiration—to
varying degrees—in TNBC cells (Fig. 1a).
To further investigate the influence of treatment on
glucose metabolism, we studied the regulation of TCA
cycle intermediates by 1,25(OH)2D3 using GC/MS in
representative cell lines of each molecular subtype,
MCF-7 (luminal) and MDA-MB-231 (TNBC) cells.
Interestingly, the levels of the investigated intermediates
were differentially impacted by 1,25(OH)2D3, where
treatment was found to reduce citrate levels and the
levels of downstream metabolites in MCF-7 cells
(Fig. 1b). In MDA-MB-231 cells on the contrary, citrate
levels were found to be increased by 1,25(OH)2D3
(Fig. 1b). Additionally, we investigated the levels of select
essential and non-essential amino acids in response to
1,25(OH)2D3 in both cell lines. While levels of all inves-
tigated amino acids were altered in both cell lines by
1,25(OH)2D3 treatment to varying degrees, a profound
increase in serine levels was observed in MCF-7 cells
(Fig. 1b). Additionally, glycine levels were found to be
reduced and increased in response to 1,25(OH)2D3 in
MCF-7 and MDA-MB-231 cells, respectively (Fig. 1b).
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In view of the effects 1,25(OH)2D3 exerted on the in-
vestigated metabolic parameters in BCa cells, we postu-
lated that such effects may at least in part be explained
by 1,25(OH)2D3-mediated changes in the expression of
metabolism-related genes. We thus performed a com-
prehensive mRNA screen of genes encoding players in-
volved in diverse metabolic processes, such as glucose,
glutamine, and fatty acid metabolism, in MCF-7 and
MDA-MB-231 cells. Furthermore, given the different
p53 backgrounds exhibited by the two investigated cell
lines, and since p53 is known to be a powerful regulator
of cell metabolism and associated processes (e.g., au-
tophagy) [24, 25], we included in our screen a number
of p53 target genes, as well as genes encoding autophagy
Fig. 1 Analysis of 1,25(OH)2D3’s metabolism-regulating effects in BCa cells. a Extracellular acidification, respiration, and impedance rates were
monitored in real-time in response to 1,25(OH)2D3 (100 nM) over the course of 3 days, followed by a 20-h recovery period, in which cells were
exposed to running medium (RM) not containing the molecule. 1,25(OH)2D3 clearly induces glycolytic rate in luminal (MCF-7 and T-47D) BCa cells
and reduces respiration rate to varying degrees in TNBC (MDA-MB-231, MDA-MB-468, and HCC-1143) cells. Values of each cell line are normalized
to measurements obtained from the respective DMSO-treated cells. Data presented are representative of 2 biological replicates. b GC/MS analysis
of TCA cycle intermediates and amino acids in select BCa cell lines treated for 72 h with 1,25(OH)2D3 (n = 4). A strong accumulation in serine is
observed with treatment in MCF-7 cells, whereas levels of citrate were differentially regulated by 1,25(OH)2D3 in both cell lines. PEP
phosphoenolpyruvate, α-KG alpha-ketoglutarate. c mRNA expression analysis of metabolism-related genes in MCF-7 and MDA-MB-231 cells in
response to a 72 h treatment with 1,25(OH)2D3. G6PD was found to be induced by 1,25(OH)2D3 in both cell lines. Relative expression was
calculated using the ΔΔCt method, with vinculin as the housekeeping gene. Data presented are the average of 2 biological replicates. G6PD
protein expression is significantly induced in MCF-7 (d) and MDA-MB-231 (e) cells by 1,25(OH)2D3 (72 h), as demonstrated by western blot and
densitometric analysis. Statistical comparison between DMSO- and 1,25(OH)2D3-treated cells was made using a two-tailed Student’s t test. P
values less than or equal to 0.05, 0.01 and 0.001 are depicted by *, **, and ***, respectively. Error bars ± SD; n = 3. G6PD mRNA (f), protein (g), and
activity (h) levels are induced by 1,25(OH)2D3 (72 h) in all BCa cell lines. i Intracellular ATP levels were assessed in BCa cells in response to 1, 2,
and 3 days of treatment with 1,25(OH)2D3. Treatment significantly induced ATP levels in MDA-MB-231 cells in 48 and 72 h, however reduced ATP
levels in MCF-7 at the latest time point
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regulators. While several investigated genes were only
mildly regulated by 1,25(OH)2D3 treatment in both
MCF-7 and MDA-MB-231 cells, a clear induction in
the mRNA levels of the G6PD gene, encoding
glucose-6-phosphate dehydrogenase, was observed in
both cell lines (Fig. 1c). Similarly, a significant induc-
tion in G6PD protein expression was observed with
1,25(OH)2D3 treatment in both cell lines (Fig. 1d, e).
G6PD catalyzes the first rate-limiting step in the PPP,
which provides cells with reducing equivalents for both
reductive biosynthesis and protection against oxidative
stress [26]. On the other hand, G6PD expression has
been shown to be elevated in cancers and its activity in-
duced by oncogenic signaling [26, 27]. With regard to
vitamin D, the promoter of the G6PD gene has been
shown to harbor vitamin D response elements [28], and
1,25(OH)2D3 has been repeatedly shown to induce ei-
ther the expression and/or activity of this enzyme in
different experimental models, including BCa [29, 30].
We then aimed to investigate if the upregulation of
G6PD expression with 1,25(OH)2D3 treatment is ob-
served in the other BCa cell lines. Indeed, G6PD mRNA
and protein levels were markedly induced with
1,25(OH)2D3 in all the investigated BCa cell lines
(Fig. 1f, g). Importantly, G6PD enzymatic activity in all
cell lines was found to be significantly increased in re-
sponse to treatment (Fig. 1h).
We also sought to investigate changes in cellular ATP
levels in response to 1,25(OH)2D3 treatment in all BCa
cell lines. In MCF-7 cells, 1,25(OH)2D3 was found to in-
duce fluctuations in cellular ATP levels over the investi-
gated time course, with an overall significant decrease
with treatment after 72 h (Fig. 1i). In MDA-MB-231
cells, no clear differences in ATP levels were observed
with treatment after 24 h; however, a profound induction
was observed after 48 and 72 h (Fig. 1i).
Seemingly pro-survival, 1,25(OH)2D3-induced metabolic
changes do not hamper the efficacy of different anti-
cancer strategies
Results of the metabolic characterization described in
the previous section indicate that certain effects induced
by 1,25(OH)2D3 might enhance cancer cell proliferation
and survival. For example, in MCF-7 cells, treatment
was found to increase intracellular serine levels and
G6PD expression and activity. G6PD, as previously men-
tioned, is a putative oncogene, whose expression signifi-
cantly correlates with reduced overall survival in ER+
and total BCa patients (Fig. 2a). Similarly, serine is a rec-
ognized onco-metabolite that is known to contribute to
both the folate and methionine cycles, thus enhancing
nucleotide biosynthesis, NADPH production, and
S-adenosylmethionine generation, possibly inducing epi-
genetic changes [31].
G6PD inhibition has been previously shown to limit
cancer cell survival [32]. To investigate if 1,25(OH)2D3’s
induction of G6PD expression and activity would ham-
per such anti-tumor strategies, G6PD was genetically
and pharmacologically inhibited in MCF-7 cells using
siRNA and DHEA, respectively, in the presence and ab-
sence of 1,25(OH)2D3, and cellular survival was assessed
by SRB assay. While 1,25(OH)2D3 treatment did not
dampen the significant reduction in cell survival in re-
sponse to G6PD knockdown, the inhibitory (anti-cancer)
effect of DHEA was found to be enhanced in the pres-
ence of 1,25(OH)2D3 (Fig. 2b).
We then aimed at investigating the underlying mechan-
ism of serine accumulation in response to 1,25(OH)2D3 in
MCF-7 cells. Serine is a non-essential amino acid that cells
acquire either by de novo synthesis, using the glycolytic
intermediate 3-phosphoglycerate (3PG) as a starting mol-
ecule, or by uptake from the medium (Fig. 2c). We there-
fore investigated changes in the mRNA expression of
players involved in serine synthesis, metabolism, and up-
take, in response to 1,25(OH)2D3 treatment of MCF-7
cells. While treatment was found to differentially regulate
the mRNA expression of enzymes in the serine synthesis
pathway (SSP), for example non-significant alteration of
PHGDH (phosphoglycerate dehydrogenase), induction of
PSAT1 (phosphoserine aminotransferase 1), and reduction
of PSPH (phosphoserine phosphatase), enzymes involved
in serine metabolism, namely serine hydroxymethyl-
transferase 1 (SHMT1) and 2 (SHMT2), as well as
thymidylate synthase (TYMS), were found to be signifi-
cantly induced with 1,25(OH)2D3 (Fig. 2d). SHMT1 and
SHMT2 are responsible for the interconversion of serine
and glycine, and, concurrently, tetrahydrofolate (THF)
and 5,10-methylene-THF [31]. The latter could be used in
the synthesis of thymidylate, in a reaction catalyzed by
TYMS, which is the intracellular target of the classical
chemotherapeutic 5-fluorouracil (5-FU) [33].
To investigate the impact of serine accumulation in
1,25(OH)2D3-treated MCF-7 cells on the efficacy of
5-FU, cells were treated with increasing concentrations
of 5-FU, alone and in combination with 1,25(OH)2D3,
and cellular survival was evaluated. The addition of
1,25(OH)2D3 was found to significantly improve 5-FU’s
anti-cancer effects (Fig. 2e). We then aimed to elucidate
whether serine accumulation was the result of increased
de novo synthesis or uptake. We therefore treated
MCF-7 cells with the small molecule PHGDH inhibitor
CBR-5884 in the presence and absence of 1,25(OH)2D3.
PHGDH catalyzes the first reaction of the SSP, namely
the conversion of 3PG to 3-phosphopyruvate (3PHP)
[31]. CBR-5884 has been shown to be toxic to cancer
cells that depend on de novo serine synthesis, but not to
cancer cells reliant on extracellular sources for serine
[34]. Mullarky et al. [34] demonstrated that MCF-7 cells
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Fig. 2 Seemingly pro-survival metabolic effects of 1,25(OH)2D3 do not hamper the efficacy of metabolism-targeting therapeutic regimens.
a Kaplan-Meier plots demonstrating the significant inverse correlation between G6PD mRNA expression and overall survival in ER+ (left) and total
(right) BCa patients. b Knocking-down G6PD in MCF-7 cells significantly reduces cell survival, independent of 1,25(OH)2D3 (100 nM; 72 h).
Statistical comparison between DMSO- and 1,25(OH)2D3-treated cells was made using a two-tailed Student’s t test. P values less than or equal to
0.05, 0.01 and 0.001 are depicted by *, **, and ***, respectively. Error bars ± SD; n = 3. Cellular survival was assessed using SRB assay, and % survival
is calculated by normalizing the absorbance value obtained with the different experimental conditions to DMSO-treated cells transfected with
negative control (NC) siRNA. 1,25(OH)2D3 significantly enhances the anti-tumor effects of DHEA assessed by SRB assay. MCF-7 cells were treated
for 72 h with increasing concentrations of DHEA in the presence of either DMSO or 1,25(OH)2D3, and % survival is calculated by normalizing the
absorbance value obtained with the different experimental conditions to DMSO-treated cells. c Schematic overview of cellular serine uptake,
synthesis, and metabolism. 3PS 3-phosphoserine. d 72 h treatment of MCF-7 cells with 1,25(OH)2D3 differentially influences the mRNA expression
of enzymes involved in serine synthesis but upregulates the expression of those involved in serine metabolism. Relative expression was calculated
using the ΔΔCt method, with vinculin as the housekeeping gene. e 1,25(OH)2D3 significantly influences cellular survival in response to amino acid
deprivation. MCF-7 cells were cultivated in medium lacking serine, glycine, or both, in the presence of either DMSO or 1,25(OH)2D3 for 72 h, after
which SRB assay was performed. 1,25(OH)2D3 was found to mildly however significantly dampen the reduction in survival of MCF-7 cells in
response to serine deprivation. 1,25(OH)2D3 was also found to enhance the efficacy of CBR-5884 and 5-FU, inhibitors of PHGDH and TYMS,
respectively, assessed by SRB assay
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are dependent on serine in the medium and were there-
fore insensitive to CBR-5884. However, upon cultivation
in serine-depleted medium, MCF-7 cells were rendered
susceptible to the drug’s toxic effects [34]. We thus pos-
tulated that an increased SSP activity in response to
1,25(OH)2D3 would render MCF-7 sensitive to
CBR-5884’s anti-tumor effects on the one hand, as well
as dampen the growth inhibiting effects of serine
deprivation on the other. Indeed, treating MCF-7 cells
with a combination of 1,25(OH)2D3 and increasing con-
centrations of CBR-5884 led to substantial inhibition of
proliferation compared to cells treated with CBR-5884
alone (Fig. 2e). Additionally, 1,25(OH)2D3 was found to
mildly however significantly reduce the sensitivity of
MCF-7 cells to serine deprivation. Altogether, these re-
sults indicate that 1,25(OH)2D3 may enhance the ability
of cells to synthesize serine. It remains unclear, however,
if the proposed increase in serine synthesis utilizes the
glycolytic metabolite 3PG or glycine as a starting inter-
mediate. In support of the latter possibility is the reduc-
tion in glycine levels and the induction in SHMT1 and 2
mRNA expression in 1,25(OH)2D3-treated MCF-7 cells.
1,25(OH)2D3 differentially regulates the AMPK-TXNIP
signaling axis in BCa cells
In view of the clear metabolic rewiring induced by
1,25(OH)2D3 in BCa cells, we hypothesized that key sig-
naling molecules involved in regulating energy levels
and glucose homeostasis might be affected by treatment.
We thus investigated changes in TXNIP expression and
AMPK signaling activation in BCa cells in response to
1,25(OH)2D3 treatment. TXNIP, originally identified by
Chen and DeLuca in HL-60 cells as the vitamin D up-
regulated protein 1 (VDUP1) [35], regulates both redox
balance and glucose uptake [36]. With regard to redox
regulation, TXNIP binds to reduced thioredoxin and
prevents its anti-oxidant actions [36]. More recent stud-
ies however have shown that TXNIP is a pivotal member
of glucose-sensing mechanisms, involving glycolytic in-
termediates, glucose transporters, and the heterodimers
MondoA-MLX [37, 38]. Briefly, an increase in glucose
uptake and subsequently glycolytic intermediates triggers
the nuclear translocation of the aforementioned hetero-
dimer, which binds to carbohydrate response elements
on the TXNIP gene, thereby inducing its expression [37].
TXNIP in turn reduces glucose uptake by reducing the
expression and inducing the internalization of glucose
transporter 1 [38]. AMPK on the other hand is a hetero-
trimeric complex that acts as an intracellular energy
gauge through sensing changes in the AMP:ATP ratio
[39]. In response to energetic stress, AMPK inhibits
energy-consuming processes such as fatty acid synthesis
and activates energy-producing processes, including glu-
cose uptake and mitochondrial respiration [39].
Recently, AMPK has been shown to induce glucose up-
take through triggering the degradation of TXNIP [38].
BCa cells were therefore treated with 1,25(OH)2D3 for
72 h, after which TXNIP levels and AMPK signaling ac-
tivity were investigated using immunoblotting. Treat-
ment was found to activate AMPK signaling, as
observed by the increased phosphorylation of acetyl coA
carboxylase (ACC; serine 79)—AMPK’s substrate—in
MCF-7 and MDA-MB-231 cells (Fig. 3a), which corre-
lates well with the alterations in ATP levels observed in
these two cell lines with 1,25(OH)2D3 treatment (Fig. 1i).
Furthermore, in cell lines expressing detectable levels of
TXNIP, namely MCF-7, T-47D, and MDA-MB-231 cells,
canonical regulation of TXNIP expression by
1,25(OH)2D3 was not observed (Fig. 3a). In fact, treat-
ment was found to reduce TXNIP levels in MCF-7 cells
(Fig. 3a), an effect that was statistically significant after
both 24 and 72 h of treatment (Fig. 3b, c). This is in line
with our previous studies demonstrating reduction of
TXNIP levels by 1,25(OH)2D3 in prostate cancer cells
[16], as well as the cell line-specific regulation of the
protein by treatment [40].
Since TXNIP engages in both redox balance and glu-
cose homeostasis [37, 41], we hypothesized that the re-
duction in TXNIP level in MCF-7 cells by treatment
may also influence such critical cellular processes. We
therefore evaluated intracellular ROS levels in DMSO-
and 1,25(OH)2D3-treated MCF-7 cells using DHE and
MitoSOX Red staining. Although 1,25(OH)2D3 was
found to significantly induce G6PD expression and activ-
ity (Fig. 1d, h) as well as intracellular serine levels in
MCF-7 cells (Fig. 1c), which together with the reduction
in TXNIP expression serve as a strong basis for
anti-oxidant activity, we observed significant ROS
accumulation in response to treatment (Fig. 3d–g;
Additional files 3 and 4: Movies S1 and S2). This is in
line with the results of Koren et al. [42], who illustrated
that 1,25(OH)2D3 may act as a pro-oxidant in MCF-7
cells by increasing the ratio of oxidized to reduced gluta-
thione. Moreover, we observed a significant reduction in
glucose uptake after 24, but not 72 h of treatment
(Additional file 5: Figure S1), indicating that the reduc-
tion in intracellular glycolytic intermediates in response
to 1,25(OH)2D3 may have led to the decrease in TXNIP
expression.
Non-canonical regulation of TXNIP by 1,25(OH)2D3 is
independent of metabolic changes
As previously mentioned, the TXNIP gene is a direct
target of the glucose-sensing transcriptional heterodi-
mer MondoA-MLX and is induced in response to an
increase in upstream glycolytic intermediates, namely
glucose-6-phosphate. We postulated that distinct
metabolic changes induced by 1,25(OH)2D3 in MCF-7
Abu el Maaty et al. Cancer & Metabolism  (2018) 6:11 Page 9 of 18
cells, including increased G6PD expression and activ-
ity, induction of the SSP, and enhanced glycolytic rate,
may contribute to the reduction in TXNIP expression
by depleting the levels of glycolytic intermediates cap-
able of inducing TXNIP levels. We thus postulated
that genetic and/or pharmacological inhibition of
such metabolic pathways in 1,25(OH)2D3-treated cells
would rescue TXNIP expression (Fig. 4a).
Since G6P is a major glycolytic metabolite implicated
in inducing TXNIP expression [43], we first investigated
the impact of G6PD induction by 1,25(OH)2D3 on
TXNIP regulation. Time-course studies of TXNIP and
Fig. 3 Regulation of AMPK signaling and TXNIP expression in BCa cells by 1,25(OH)2D3. a The AMPK-TXNIP signaling axis was found to be differentially
regulated by a 72-h treatment with 1,25(OH)2D3 (100 nM). AMPK signaling was found to be induced and TXNIP expression reduced in MCF-7 cells in
response to treatment. Western blot and densitometric analysis of TXNIP expression in MCF-7 cells treated for 24 (b) and 72 h (c) with 1,25(OH)2D3.
Statistical significance between DMSO- and 1,25(OH)2D3-treated cells is calculated using a two-tailed Student’s t test, where p values less than or equal
to 0.05, 0.01, and 0.001 are depicted in the figures by *, **, and ***, respectively. Error bars ± SD; n = 3. d–g 72 h treatment with 1,25(OH)2D3
significantly induces intracellular ROS levels. Microscopic analysis of cellular superoxide using DHE staining (d) and associated quantification (e).
Hoechst dye was used to stain nuclei. Mitochondrial superoxide was stained using MitoSOX Red, and mitochondria were stained using MitoTracker
Green (f). Microscopic images were taken every 15 min for 5 h, and fluorescence intensity of MitoSOX Red was quantified (g)
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Fig. 4 (See legend on next page.)
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G6PD mRNA and protein regulation by 1,25(OH)2D3 il-
lustrated that the initial induction in TXNIP mRNA
levels by treatment (1–3 h) was found to be largely at-
tenuated at 6 h, coinciding with the induction in G6PD
mRNA levels by 1,25(OH)2D3 (Fig. 4b). Similarly, on the
protein level, the reduction and induction of TXNIP and
G6PD levels, respectively, in response to treatment, first
occurs after 12 h (Fig. 4c), indicating that shunting of
G6P into the PPP by G6PD may be responsible for
TXNIP reduction. We then knocked-down G6PD levels
in MCF-7 cells using siRNA and investigated TXNIP
mRNA and protein regulation by 1,25(OH)2D3. Add-
itionally, cells were treated with either DMSO or
1,25(OH)2D3 for 48 h, and DHEA—the non-competitive
inhibitor of G6PD [44]—was added to the conditioned
medium for an additional 24 h, after which TXNIP levels
were also investigated. Independent of 1,25(OH)2D3,
knocking-down G6PD levels were not found to influence
TXNIP mRNA levels, whereas different concentrations
of DHEA were found to induce TXNIP mRNA levels
(Fig. 4d). Furthermore, TXNIP protein expression was
found to be largely depleted, and reduced in a
dose-dependent manner, in cells with knocked-down
G6PD levels, and in DHEA-treated cells, respectively, in-
dependent of 1,25(OH)2D3 (Fig. 4e). We therefore con-
cluded that the induction in G6PD expression and
activity by treatment does not contribute to the reduc-
tion in TXNIP expression.
To assess the contribution of other 1,25(OH)2D3-in-
duced metabolic changes to TXNIP regulation, MCF-7
cells were treated with increasing concentrations of Na
oxamate and AZD 3965, inhibitors of lactate dehydro-
genase and monocarboxylate transporter (MCT) 1, re-
spectively, as well as CBR-5884, alone and in
combination with 1,25(OH)2D3. While AZD 3965 and
CBR-5884 led to slight increases in TXNIP protein
levels, all inhibitors were found to reduce TXNIP ex-
pression in the presence of 1,25(OH)2D3 (Fig. 4f–h), in-
dicating that inhibition of one metabolic pathway in
1,25(OH)2D3-treated cells does not lead to an accumula-
tion of glycolytic intermediates since such metabolites
might be shunted into other activated pathways.
1,25(OH)2D3 reduces TXNIP expression through inducing
its proteasomal degradation
Since 1,25(OH)2D3 treatment had no profound impact
on TXNIP mRNA levels at time points in which pro-
tein levels were found to be clearly reduced by treat-
ment (12, 24, and 72 h), we speculated that
1,25(OH)2D3 reduces TXNIP levels through inducing
its proteasomal degradation. Numerous studies have
demonstrated that 1,25(OH)2D3 influences protein
stability through a number of distinct mechanisms,
namely regulating the expression of players in the
ubiquitin proteasomal pathway, proteases, and prote-
ase inhibitors [45]. Moreover, TXNIP degradation
through the ubiquitin proteasomal pathway has been
demonstrated by studies implicating the E3 ubiquitin
ligase ITCH as well as AMPK signaling in TXNIP
stability [38, 46].
To investigate the possible degradation of TXNIP by
1,25(OH)2D3, the proteasomal and lysosomal inhibitors
MG-132 and leupeptin, respectively, were added to the
conditioned medium of DMSO- and 1,25(OH)2D3-treated
MCF-7 cells 6 h prior to the end of the treatment period
(72 h). A similar treatment plan was employed for
2-deoxyglucose, which was used as a positive control of
TXNIP regulation, since this molecule is phosphorylated
by hexokinase to yield 2-deoxyglucose-6-phosphate, which
accumulates intracellularly, thus inducing the nuclear
translocation of MondoA/Mlx leading to an increase in
TXNIP expression [37]. MG-132 and 2-deoxyglucose, but
not leupeptin, were found to rescue TXNIP levels in
1,25(OH)2D3-treated cells (Fig. 5a).
In view of this, we proposed that 1,25(OH)2D3 may
influence TXNIP proteasomal degradation by either in-
ducing ITCH expression or by enhancing its interaction
with TXNIP. Assessment of changes in ITCH mRNA
(See figure on previous page.)
Fig. 4 TXNIP regulation by 1,25(OH)2D3 is independent of metabolic reprogramming. a Schematic overview of treatment-induced metabolic
changes that may reduce levels of glycolytic intermediates capable of inducing the nuclear translocation of MondoA/MLX and hence TXNIP
expression. Genetic and/or pharmacological strategies for inhibiting key metabolic players are depicted. b Time-dependent increase in G6PD
mRNA expression in MCF-7 cells with 1,25(OH)2D3 (100 nM) is associated with an attenuation of the initial increase in TXNIP mRNA levels with
treatment. Upper and lower ends of floating bars represent maximum and minimum values, respectively, whereas lines in the middle represent
the means. The ΔΔCt method was used to calculate the relative expression with vinculin as the housekeeping gene. The data are obtained from
two biological replicates. c Similar to the trend observed on the mRNA level, the induction in G6PD protein level in response to 1,25(OH)2D3 first
occurs after 12 h, which coincides with the first reduction in TXNIP protein expression. d Co-treatment with DHEA, but not knocking-down G6PD
levels, elevates TXNIP mRNA levels in 1,25(OH)2D3-treated MCF-7 cells. Cells transfected with either anti-G6PD siRNA or a NC were treated with
1,25(OH)2D3 for 72 h, whereas increasing concentrations of DHEA were added to the conditioned medium of MCF-7 cells treated for 48 h with
either DMSO or 1,25(OH)2D3, for an additional 24 h. e G6PD inhibition using siRNA or DHEA reduces TXNIP protein expression independent of
1,25(OH)2D3. f–h Western blot analysis of TXNIP expression in MCF-7 cells treated with a combination of either DMSO or 1,25(OH)2D3 and various
metabolic inhibitors. Cells were initially treated with DMSO or 1,25(OH)2D3 for 48 h, after which increasing concentrations of the different
inhibitors were added to the conditioned medium for an additional 24 h. All inhibitors were found to reduce TXNIP protein levels in 1,25(OH)2D3-
treated cells. In the absence of 1,25(OH)2D3, AZD 3965 and CBR-5884 were found to mildly induce TXNIP levels
Abu el Maaty et al. Cancer & Metabolism  (2018) 6:11 Page 12 of 18
and protein levels in MCF-7 cells in response to
1,25(OH)2D3 did not reveal an induction in ITCH
expression by treatment (Fig. 5b, c). Similarly, overall
protein ubiquitination in MCF-7 cells was unchanged by
1,25(OH)2D3 treatment (Fig. 5d). Furthermore, 1,25(OH)2D3
was not found to markedly alter the levels of ITCH
co-precipitating with TXNIP (Fig. 5e). We then hypothe-
sized that AMPK, which was found to be activated in re-
sponse to 1,25(OH)2D3 in MCF-7 cells (Fig. 3a), may be
implicated in TXNIP degradation by 1,25(OH)2D3. We
therefore knocked-down AMPK 1 levels in MCF-7 cells
and investigated TXNIP protein expression in response
to a 24- and 72-h treatment with 1,25(OH)2D3.
Interestingly, the reduction in TXNIP expression by
1,25(OH)2D3 was observed in cells with knocked-down
AMPK 1 levels (Fig. 5f ).
Additionally, we postulated that TXNIP degradation
by 1,25(OH)2D3 may be Ca
2+-dependent, for example,
by increasing intracellular Ca2+ levels leading to AMPK
activation or by activating Ca2+-dependent proteases,
namely calpains. To this end, we employed calcipotriol,
a hypo-calcemic analog of 1,25(OH)2D3, as well as the
Fig. 5 1,25(OH)2D3 induces proteasomal degradation of TXNIP in MCF-7 cells. a The reduction in TXNIP protein levels by 1,25(OH)2D3 (100 nM) in
MCF-7 cells is rescued by MG-132 (5 μM) or 2-deoxyglucose (10 mM), but not leupeptin (20 μM). The various molecules were added to the
conditioned medium of DMSO- and 1,25(OH)2D3-treated (66 h) MCF-7 cells, for an additional 6 h. b, c ITCH mRNA and protein expression is not
markedly influenced by 1,25(OH)2D3. Relative expression was calculated using the ΔΔCt method with vinculin as the housekeeping gene. Error
bars ± SD; n > 3. d Overall protein ubiquitination in MCF-7 cells was not changed by 1,25(OH)2D3 treatment. e Co-immunoprecipitation studies
illustrate that the TXNIP-ITCH interaction is not altered by 1,25(OH)2D3 treatment of MCF-7 cells. f Negative regulation of TXNIP protein expression
by 1,25(OH)2D3 is observed in MCF-7 cells with knocked-down AMPKα1 levels. g The non-calcemic 1,25(OH)2D3 analogue, calcipotriol (100 nM;
72 h) induces similar effects on TXNIP expression as 1,25(OH)2D3. The cell permeable Ca
2+ chelator BAPTA-AM (20 μM) does not hamper
1,25(OH)2D3’s effects on TXNIP expression. BAPTA-AM was added to the conditioned medium of DMSO- and 1,25(OH)2D3-treated MCF-7 cells, 2 h
prior to the end of the treatment period (72 h)
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cell permeable Ca2+ chelator BAPTA-AM. Similar to
the parental molecule, calcipotriol treatment led to a
reduction in TXNIP levels in MCF-7 cells (Fig. 5g).
Moreover, addition of BAPTA-AM to the conditioned
medium of 1,25(OH)2D3-treated MCF-7 cells did not
rescue TXNIP levels (Fig. 5g). These data indicate the
lack of involvement of Ca2+ signaling in mediating
1,25(OH)2D3’s effects on TXNIP expression.
Negative regulation of TXNIP protein levels by
1,25(OH)2D3 is possibly ER dependent
Previous reports have highlighted the ability of 1,25(OH)2D3
to decrease the expression of ER in BCa cells [47, 48].
Since estradiol stimulates glucose uptake and metabolism in
BCa cells [49, 50], we investigated the possible involvement
of ER in 1,25(OH)2D3’s regulation of TXNIP. Firstly, we
sought to confirm the reduction in ER mRNA and pro-
tein expression in MCF-7 cells by 1,25(OH)2D3. Indeed,
treatment was found to reduce ER expression in MCF-7
cells (Fig. 6a–c). We then co-treated cells with ER signaling
regulators, namely the selective ER modulator tamoxifen,
and estradiol, in the presence of either DMSO or
1,25(OH)2D3. Tamoxifen, independent of 1,25(OH)2D3, was
found to reduce TXNIP protein levels in a time-dependent
manner (Fig. 6d). Estradiol on the other hand did not mark-
edly influence TXNIP protein levels in either DMSO- or
1,25(OH)2D3-treated cells (Fig. 6e). On the mRNA level,
both ER agonist and antagonist did not significantly alter
TXNIP expression, independent of 1,25(OH)2D3 (Fig. 6f).
Given TXNIP’s role in glucose homeostasis, and since
GLUT1 expression has been shown to be induced by es-
tradiol treatment [51], we aimed to study the influence of
co-treating MCF-7 cells with ER modulators and either
DMSO or 1,25(OH)2D3 on glucose uptake. While differ-
ent concentrations of tamoxifen markedly reduced glucose
uptake, 1,25(OH)2D3 co-treatment was found to signifi-
cantly attenuate this effect (Fig. 6g). Estradiol treatment
on the other hand led to a concentration-dependent re-
duction in glucose uptake, an effect that was not largely
impacted by 1,25(OH)2D3 co-treatment (Fig. 6g).
Discussion
Calcitriol and its analogues are known to strongly influ-
ence the survival of BCa cells through multiple mecha-
nisms [3, 4]. Recent studies have illustrated the ability of
this molecule to influence energy utilization of different
cancerous and non-cancerous experimental models, in-
cluding transformed breast epithelial cells [13–16, 52, 53].
In the current study, we report 1,25(OH)2D3-induced
metabolic reprogramming of BCa cell lines representing
distinct molecular subtypes. We performed in-depth
analyses of 1,25(OH)2D3’s metabolic effects using a com-
bination of biosensor technology, GC/MS-based metabo-
lomics, gene expression analysis, and assessment of
overall energy levels. We show that although metabolic re-
wiring occurs in all investigated cell lines in response to
treatment, both similarities and differences in the meta-
bolic phenotypes are observed. For example, while differ-
ential regulation of glucose and amino acid metabolism,
as well as energy-related signaling molecules was ob-
served, 1,25(OH)2D3 was found to induce G6PD expres-
sion and activity in all cell lines.
Findings of the current study demonstrate that modu-
lation of metabolic networks may be a mechanism
through which 1,25(OH)2D3 exerts anti-tumor effects.
Importantly, results highlight certain metabolic “weak
points” that 1,25(OH)2D3-treated cells exhibit, which
could be candidate targets for combination chemother-
apy. We propose that exploiting such metabolic alter-
ations may be key to improving the outcome of vitamin
D-based therapies in clinical trials of cancer treatment.
For example, induction in the expression and activity of
the metabolic oncogene G6PD by 1,25(OH)2D3 may en-
hance cancer cells’ survival, due to the generated
NADPH, which could be used for reductive biosynthesis
and anti-oxidant defense [26]. NADPH may also con-
tribute to xenobiotic metabolism and elimination by
cytochrome P450 enzymes [26] and thus may also amp-
lify CYP24A1-dependent degradation of 1,25(OH)2D3.
Therefore, G6PD-inhibiting therapeutic regimens may
hamper 1,25(OH)2D3’s catabolism on the one hand, as
well as limit cellular growth on the other. Noteworthy is
that while 1,25(OH)2D3 (72 h) did not substantially in-
hibit MCF-7 proliferation (Fig. 2b)—supporting a
counter-therapeutic role for G6PD activation by treat-
ment—intracellular ROS levels were found to be induced
by 1,25(OH)2D3 (Fig. 3d–g), indicating that the increas-
ing NADPH production may not have been used for
anti-oxidant defense. Studies have illustrated a
context-dependent role of 1,25(OH)2D3 in regulating
redox balance, with both pro- and anti-oxidant effects re-
ported in different experimental systems [28, 42, 54]. Fur-
thermore, while NADPH has been mainly associated with
ROS detoxification, it may also be used by NADPH oxi-
dases to produce ROS [55]. Importantly, 1,25(OH)2D3 was
not found to hamper the reduction in cellular proliferation
by genetic inhibition of G6PD and was found to enhance
the anti-proliferative effects of DHEA.
Another target for combinatorial strategies in vitamin
D-based chemotherapies is serine metabolism. Combin-
ation of 1,25(OH)2D3 with either 5-FU or CBR-5884 was
found to be more potent than the corresponding
mono-treatments (Fig. 2e), despite 1,25(OH)2D3 alone
leading to serine accumulation (Fig. 1b), and upregu-
lation of expression of serine metabolism-related
genes in MCF-7 cells (Fig. 2d). Although aberrations
in serine metabolism have been previously linked to
chemo-resistance [56, 57], we postulate that the
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demonstrated diversity of 1,25(OH)2D3’s metabolic ef-
fects may enable anti-cancer drugs overcome this po-
tential therapeutic hurdle.
We also investigated the regulation of TXNIP by
1,25(OH)2D3 in BCa cells. Although initially described
as the VDUP1 [35], it remained unclear if 1,25(OH)2D3
induces TXNIP expression in different cell types since
this canonical regulation has only been observed in
HL-60 cells [58], and promoter analysis of mouse
VDUP1 did not demonstrate the presence of VDRE [59].
Additionally, we have recently shown that calcitriol in-
duces non-canonical regulation of TXNIP in the prostate
Fig. 6 Reduction of TXNIP expression in MCF-7 cells by 1,25(OH)2D3 is possibly ER-dependent. a–c 1,25(OH)2D3 (100 nM) treatment significantly
reduces ER mRNA (72 h) and protein expression in MCF-7 cells. Relative expression was calculated using the ΔΔCt method, with vinculin as the
housekeeping gene. Statistical significance between DMSO- and 1,25(OH)2D3-treated cells is calculated using a two-tailed Student’s t test, where p
values less than or equal to 0.05, 0.01, and 0.001 are depicted in the figures by *, **, and ***, respectively. Error bars ± SD; n = 3. Tamoxifen
(10 μM) treatment (d), but not estradiol (100 nM) (e), reduces TXNIP protein expression in a time-dependent manner. f Non-significant regulation
of TXNIP mRNA levels is observed in MCF-7 cells treated for 24 h with either tamoxifen or estradiol, alone and in combination with 1,25(OH)2D3.
g Glucose uptake in MCF-7 cells is significantly reduced by various concentrations of tamoxifen (24 h), an effect that is significantly ablated in the
presence of 1,25(OH)2D3. Estradiol reduces glucose uptake in a concentration-dependent manner, with 1,25(OH)2D3 only influencing regulation of
glucose uptake in response to 10 nM treatment with estradiol
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cancer cell line LNCaP [16], and that in HL-60 cells, i.e.,
the cell line in which the original identification was made,
induction in TXNIP protein levels by 1,25(OH)2D3
depended on the availability of glucose in the culture
medium [40]. Furthermore, screening TXNIP regulation by
1,25(OH)2D3 in multiple cancer cell lines of different tissue
origins demonstrated either induction, reduction, or not
change in TXNIP levels by treatment [40]. In the present
study, we observed that not all BCa cell lines exhibit detect-
able levels of TXNIP, and in those that do, treatment either
reduces or has no clear effect on TXNIP protein expression
(Fig. 3a). These findings indicate that TXNIP, a putative
tumor suppressor, may not be central to calcitriol’s
anti-tumor effects. Moreover, the reduction in TXNIP levels
by 1,25(OH)2D3 in MCF-7 contrasts the accumulation of
intracellular ROS since TXNIP is known to bind to reduced
thioredoxin, thus inhibiting its anti-oxidant activity.
Conclusions
In spite of many studies demonstrating the ability of cal-
citriol to inhibit BCa cell survival, few have focused on
the molecule’s role in regulating cells’ energy utilization
and nutrient-sensing. 1,25(OH)2D3 appears to induce di-
verse changes in the levels and/or activity of key en-
zymes, metabolites, and signaling molecules involved in
energy metabolism, leading to multi-faceted metabolic
phenotypes in BCa cells. Distinct metabolic vulnerabil-
ities have been identified in 1,25(OH)2D3-treated BCa
cells, which may serve as targets for combination
chemotherapy. For example, by combining 1,25(OH)2D3
with G6PD-inhibiting regimens, substantial anti-tumor
effects were observed. Additionally, while TXNIP has
been previously identified as a tumor suppressor and a
vitamin D target gene, our results indicate that activa-
tion of TXNIP expression by calcitriol is not achieved in
different BCa cell lines, and that in MCF-7 cells, the re-
duction in the TXNIP level by treatment is potentially
due to rewiring of glucose metabolism, protein degrad-
ation, and cross-talk between VDR and ER signaling.
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